I n an open, p r o s p e c t i v e , non-comparative s t u d y , 37 p r e v i o u s l y t r e a t e d (PrTr) (with e x t r a c t e d HGR) and 5 p r e v i o u s l y u n t r e a t e d (PrUn) GHD c h i l d r e n ( h e i g h t (Ht) < 3 p e r c e n t i l e o r Ht v e l o c i t y (Vel) < 4 cmlyear; max.serum-GH < 10 ng/ml i n a t l e a s t two standard s t i m u l a t i o n t e s t s ) were given Bio-HGH (Somatropin-Lilly) s.c.0.06 mglkg t h r e e times a week t o a max. of 8 mg p e r week. Treatment with Bio-HGll began a t l e a s t 5 months a f t e r t r e a t m e n t w i t h e x t r a c t e d HGII had ceased. Height was measured w j t h i n 2 months a f t e r previous t r e a t m e n t was discontinued. Lower l e g l e n g t h (LLL) measurements were s t a r t e d 6 weeks b e f o r e t r e a t m e n t w i t h Bio-IIGII by u s i n g a knemometer. Ht Vel (cm/yr) and LLL Vel (mm/yr) a r e shown i n the t a b l e (mean+SD).
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EFFICACY OF BIOSYNTHETIC HUMAN GROWTH HORMONE (BIO-BGH) I N STIMULATING GROWTH I N PREPUBERTAL (PRE) AND PUBERTAL (PUB) CHILDREN W I T H GROWTI1 HORMONE DEFICIENCY (GHD)
I n an open, p r o s p e c t i v e , non-comparative s t u d y , 37 p r e v i o u s l y t r e a t e d (PrTr) (with e x t r a c t e d HGR) and 5 p r e v i o u s l y u n t r e a t e d (PrUn) GHD c h i l d r e n ( h e i g h t (Ht) < 3 p e r c e n t i l e o r Ht v e l o c i t y (Vel) < 4 cmlyear; max.serum-GH < 10 ng/ml i n a t l e a s t two standard s t i m u l a t i o n t e s t s ) were given Bio-HGH (Somatropin-Lilly) s.c.0.06 mglkg t h r e e times a week t o a max. of 8 mg p e r week. Treatment with Bio-HGll began a t l e a s t 5 months a f t e r t r e a t m e n t w i t h e x t r a c t e d HGII had ceased. Height was measured w j t h i n 2 months a f t e r previous t r e a t m e n t was discontinued. Lower l e g l e n g t h (LLL) measurements were s t a r t e d 6 weeks b e f o r e t r e a t m e n t w i t h Bio-IIGII by u s i n g a knemometer. Ht Vel (cm/yr) and LLL Vel (mm/yr) a r e shown i n the t a b l e (mean+SD).
Before o r r e l a t e d more s i g n i f i c a n t l y with Ht Vel d u r i n g (r=0.75) than b e f o r e (r=0.47) Bio-HGH treatment. Because LLL was measured only 6 weeks b e f o r e Bio-HGH was s t a r t e d , t h e LLL Vel probably r e f l e c t s more a c c u r a t e l y the e f f i c a c y of Bio-HGli i n PrTr p a t i e n t s . 
CLINICAL STUDIES I N GROWTH HORMONE DEFICIENT PATIENTS (GHDP) USING DIFFERENT PREPARATIONS OF 192-RECOMBINANT HUMAN GROWTH HORMONE (192-rhGH), S I , S I I , S I I I , ACCOR-DING TO THEIR E.COL1 PROTEIN CONCENTRATION (ECPC). 192-rhGH (Somatrem) w i t h ECPC of 285-1400 ( S I )
, 170-30 ( S 1 I ) a n d (10 ( S I I I ) / n g / v i a l was used i n 3 s t u d i e s i n GHDP n o t p r e v i o u s l y ("new") o r p r e v i o u s l y ( " o l d " ) t r e a t e d w i t h pit-hGA. I n 8 "old" pat i e n t s ( d u r a t i o n l month ( m ) ) , g l u c o s e and i n s u l i n responses i n t h e OGTT, i n s u l i n binding i n e r y t h r o c y t e s and somatomedin a c t i v i t y (SMA) were s i m i l a r on pit-hGH o r S I . Absence of hGH-antibodies (hGH-ab) d u r i n g t h i s p e r i o d . On S I I ( 9 p a t i e n t s , d u r a t i o n 9-12 m.) and S I I I (21 p a t i e n t s , planned d u r a t i o n 1 y e a r , r e s u l t s p r e s e n t e d of 6 m ) , "new" p a t i e n t s experimented t y p i c a l catch-up growth and t h e o l d ones maintained t h e i r p r e v i o u s growth v e l o c i t y (g.v.1. SMA c o r r e l a t e d w i t h g.v. and a d u l t h e i g h t prognosis improved throughout t r e a t m e n t . hGH-ab t e s t was p o s i t i v e on S I I a t 3 m. of t r e a t m e n t i n 77% o f c a s e s and i n 88% a t 9-12 m., w h i l e on S I I I a t 3 m. and 6 m. hGH-ab t e s t was p o s i t i v e i n o n l y 8 % and 16% of c a s e s n o t prev i o u s l y t r e a t e d w i t h S I I b u t again i n 88% of p a t i e n t s p r e v i o u s l y t r e a t e d w i t h S I I . Binding c a p a c i t y of hGH-ah was very low. ECP-ab were a l r e a d y p o s i t i v e i n 33% a t o n s e t and i n c r e a s e d moderately l at e r . Thus 192-rhGH promotes g .~. and SMA and, a s i n t h e m a j o r i t y of c a s e s hGH-ab t e s t is a l r e a d y p o s i t i v e a t 3 m., S I I I i s c l e a r l y l e s s a n t i g e n i c than S I I . 
P a t i e n t s p r e v i o u s l y t r e a t e d w i t h S I I poss i b l y developed an anamnestic response on S I I I . No o t h e r s i d

COMPARISON OF THE LIPOLYTIC POTENCY OF PITUITARY-DERIVED AND BIOSYNTHETIC GROWTH HORMONE I N IIYPOPITUI-TARY CHILDREN.
Whether l i p o l y s i s i s an i n t r i n s i c p r o p e r t y of t h e growth hormone (GH) molecule o r i s due t o contaminants of p i t u i t a r y o r i g i n remains c o n t r o v e r s i a l . We t h e r e f o r e compared t h e r i s e i n plasma f r e e f a t t y a c i d (FFA) l e v e l s measured w i t h t h e Nefa Quick "BMY" k i t , Boehringer) induced by e i t h e r p i t u i t a r y G H (pit-GH, Nanormon, ord disk) o r b i o s~n t h e t i c G H (syn-GH, Somatonorm, Kabi)
i n 34 h y p o p i t u i t a r y c h i l d r e n (age 5 -18 y e a r s , peak plasma G H < 5 nglml a f t e r i n s u l i n and glucagon t o l e r a n c e t e s t s ) . The p a t i e n t s were admitted a f t e r an o v e r n i g h t f a s t and f a s t e d u n t i l 1230 h r on both s t u d y days. On day 1 , no i n j e c t i o n was given. On day 2, 0 . 2 Ulkg of e i t h e r pit-GH (N=5, group A) o r syn-GH (N=29, group B) was given IM a t 0830 h r . The FFA l e v e l s a t 1230 h r a r e expressed a s % of t h e 0830 h r v a l u e . I n group A, mean (+ SEM) plasma FFA l e v e l s a t 1230 h r were 138.7 + 9.8 % of the0830 h r v a l u e on day 1 and 233.1 20.0 % on day 2.
I n group B, they were 130.3 + 10.9 % and 267 22.6 % on days 1 and 2 , r e s p e c t i v e l y . Thus, both GH p r e p a r a t i o n s induced a r i s e i n plasma FFA l e v e l s g r e a t e r t h a n t h a t induced by f a s t i n g a l o n e (p < 0.001) but t h e two G H p r e p a r a t i o n s were n o t s i g n i f i c a n t l y d i f f e r e n t from each o t h e r (p > 0 . 2 ) . We conclude t h a t t h e a c u t e l i p o l y t i c e f f e c t probably r e p r e s e n t s an i n t r i n s i c p r o p e r t y oE t h e G H molecule. 
SEX DIFFkRENCES IN GONADAL ESTRADIOL (E2) AND ESTRONE
(El) CONCENTRATIONS IN INFANCY To clarify the origin of estrogens in infant blood, we measured El and E2 in the gonads of 50 girls and 64 boys deceased by sudden death between birth and 2 years of age. In both sexes, E2 was the major gonadal estrogen which exceeded El almost tenfold in the ovaries and twice in the testes. Thus, there was a clear sex difference in gonadal estrogen concentrations. On an average, girls had 8 times higher E2 and twice as high El concentrations in their gonads than boys. As in plasma, E2 concentrations were highest in ovaries of 2 to 4 months old girls (2 -55 nglg) and in testes of I to 3 months old boys (0.6 -6.4 nglg). Ovarian E2 concentrations decreased to values below 3 ng/g until the end of the 1st year of life, testicular E2 reached values below 1 nglg already by 6 months of age. The gonadal steroidogenic activity paralleled changes in gonadal morphology. Ovarian weights showed a similar pattern of rise and fall as the E2 concentrations, the biggest ovaries consisting of multiple macroscopic cysts. In boys, testicular E2 closely correlated with Leydig cell development and testicular testosterone concentrations. We conclude that the surge o f E2 in the blood of infant girls and boys originates from ovarian follicles and testicular Leydig cells, respectively, which develop under the influence o f the characteristic post-natal gonadotropin surge. '8
